The B-Cell Lymphomas (BCL) accounts for most of the non-Hodgkin Lymphomas (NHL). In case of BCL, the diseased body makes too many abnormal B-cells. The lymphomas has the ability to grow around any lymph nodes in the body, such as small glands in the neck, armpits, and groin. Other parts of the body include spleen, bone marrow, thymus, adenoids, tonsils, and stomach. Some of the most common B-cell Lymphomas include diffuse large BCL, follicular lymphomas, chronic lymphocytic leukemia (CLL), mantle cell lymphomas (MCL), and marginal zone lymphomas, among others.
Globally, DLBCL accounts for up to 40% of all cases of NHL. About 80-85% of the NHLs are of the B-cell origin. Further, as per the Lymphoma Research Foundation, in western countries, about 25-30% of NHL cases diagnosed in adults are DLBCL-NOS, which is higher than the percentage in emerging markets. The treatment is usually personalized to the stage of disease and type of lymphoma. The advancement observed in pipeline are toward creating biologics and precision medicine, with more accuracy and faster relief.
This report by Mordor Intelligence provides extensive insights of the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world are given, with data obtained from multiple sources. The report also includes a list of key sponsors, having pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated, based on the information procured from various stake holders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation, by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation, by Status
7.6 Other Statuses
8. Pipeline Therapeutic Assessment (Infographic Charts and Brief description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence